id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-N-2174-0006,FDA,FDA-2022-N-2174,Oncologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,Notice,Request for Comments,2023-03-02T05:00:00Z,2023,3,2023-03-02T05:00:00Z,2023-04-28T03:59:59Z,2023-04-24T01:00:34Z,2023-04268,0,0,090000648573e338
FDA-2022-N-2174-0004,FDA,FDA-2022-N-2174,Oncologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,Notice,Request for Comments,2023-01-26T05:00:00Z,2023,1,2023-01-26T05:00:00Z,2023-02-25T04:59:59Z,2023-01-29T00:54:17Z,2023-01553,0,0,090000648560cdb0
FDA-2022-N-2174-0002,FDA,FDA-2022-N-2174,Oncologic Drugs Advisory Committee; Cancellation,Notice,Meeting,2022-11-09T05:00:00Z,2022,11,2022-11-09T05:00:00Z,,2022-11-09T13:40:59Z,2022-24470,0,0,090000648549d61a
FDA-2022-N-2174-0001,FDA,FDA-2022-N-2174,Oncologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,Notice,Request for Comments,2022-09-22T04:00:00Z,2022,9,2022-09-22T04:00:00Z,2022-11-22T04:59:59Z,2022-12-28T14:01:42Z,2022-20524,0,0,090000648534f0fd